Does Remicade Cause Fatigue?
Yes, fatigue is a reported side effect of Remicade (infliximab), occurring in 3-10% of patients across clinical trials for conditions like Crohn's disease, rheumatoid arthritis, and psoriasis.[1][2] It's typically mild to moderate and linked to the drug's immune-modulating effects, which can disrupt energy levels during or after infusions.
How Common Is Fatigue with Remicade?
In pivotal trials:
- Rheumatoid arthritis: Up to 9% of patients.
- Crohn's disease: Around 5-7%.
- Ulcerative colitis: 3-6%.[1][3]
Post-marketing reports note higher rates in real-world use, especially with long-term therapy or combination with other immunosuppressants.
Why Does Remicade Cause Fatigue?
Remicade blocks TNF-alpha, reducing inflammation but sometimes triggering systemic responses like cytokine shifts or mild infections, leading to tiredness. Infusion reactions (fever, chills) can exacerbate it in 20% of first doses.[2][4] Pre-medication with acetaminophen or antihistamines often helps.
How Long Does Fatigue Last After a Remicade Infusion?
Most cases resolve within 24-48 hours post-infusion. Persistent fatigue beyond a week may signal infection, anemia, or disease progression—prompt medical evaluation is needed.[3][5]
What Do Patients Say About Remicade Fatigue?
User reviews on platforms like Drugs.com average 6.5/10, with fatigue cited by 15-20% of reviewers as a top complaint, often described as "crashing" energy for days.[6] Some report improvement after dose adjustments.
Managing Fatigue on Remicade
- Hydrate and rest post-infusion.
- Check for underlying issues like low iron or thyroid problems.
- Doctors may switch to subcutaneous alternatives like Inflectra (biosimilar).[4][7]
Discuss with your provider before changes.
Remicade vs. Biosimilars or Alternatives for Less Fatigue?
Biosimilars like Inflectra or Renflexis show similar fatigue rates (4-8%) but may have fewer infusion reactions due to manufacturing tweaks.[1][7] Oral alternatives like Stelara (ustekinumab) report lower fatigue (2-5%) in head-to-head studies.[3]
Sources
[1]: Remicade Prescribing Information (Janssen)
[2]: FDA Label for Infliximab
[3]: ClinicalTrials.gov summaries for INFLI-1/ACCENT trials
[4]: Drugs.com Remicade Side Effects
[5]: Crohn's & Colitis Foundation Guidelines
[6]: Drugs.com User Reviews
[7]: DrugPatentWatch.com - Infliximab Patents